Alcon reports second-quarter results on August 11 carrying the weight of a bruising prior print and a stock that is still well below where it started the year.
The most striking feature of the setup is what happened last time. The May earnings release sent the stock down more than 13% in a single session, and the losses extended to nearly 15% over the following five days. That reaction now frames everything heading into today's print. The shares have since clawed back ground — up 7% over the past month and 3% on the week to CHF 58.32 — but remain sharply lower year-to-date. The recovery has been real, but it has not erased the damage.
Short sellers are not making a crowded bet against that recovery. Short interest is modest, and borrow availability is extraordinarily loose — more than 1,200% of current short interest is available to lend, meaning the lending pool is barely being used. Cost to borrow has nudged higher, roughly 44% above last week's level at 1.16%, but in absolute terms remains low. The ORTEX short score of 33 ranks in the middle of the universe, and the direction of travel in short positioning gives no strong signal either way. Borrow conditions simply do not tell a bearish story here.
The debate instead centres on whether Alcon can deliver a cleaner operational result than it managed in May. A recent ORTEX note flags that analysts were projecting roughly 21% upside even as the stock lagged, pointing to bulls who believe strong visioncare brands and new product launches will reassert themselves. Bears counter that margin pressure and slower-than-expected procedure volume growth were the root cause of the May miss, and that those headwinds have not fully cleared. Forward EPS momentum over 90 days ranks in the 72nd percentile — a positive signal on estimate trajectory — but the EPS surprise factor ranks only in the 33rd percentile, meaning the company has a mixed track record on actually meeting those expectations. The PE multiple has drifted up about 0.76 turns over the past month as the stock recovered, compressing any valuation cushion.
Institutional ownership tells a quieter story. Vanguard entered the register with a 3.9% stake in the most recent reported period, while FMR added roughly 1.7 million shares. Those are passive and long-only flows, consistent with an ownership base that is not rushing for the exits. Among closer-traded peers, TMDX gained nearly 10% on the week and SHL added 7%, suggesting the broader med-tech tape has been constructive — a backdrop that gives Alcon a degree of cover if the print lands in line.
Today's report is ultimately a test of whether management can explain what went wrong in May and demonstrate that volume trends, particularly in surgical equipment and premium intraocular lenses, have stabilised enough to restore confidence in the full-year margin trajectory.
See the live data behind this article on ORTEX.
Open ALC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
